Capital Rx Drug Recall Report

APRIL 2024

Capital Rx

Welcome to the Capital Rx Drug Recall Report. This report is designed to keep you up to date on the latest FDA Class 1 and Class 2 recalled drugs and market withdrawals that impact our members. It is one of the many ways we, at Capital Rx, demonstrate our commitment to providing clients and partners the tools and resources they desire.

WHO WE ARE

Capital Rx is a full-service pharmacy benefit manager (PBM) and pharmacy benefit administrator (PBA), advancing our nation's electronic healthcare infrastructure to improve drug price visibility and patient outcomes. As a Certified B Corp™, Capital Rx is executing its mission through the deployment of JUDI®, the company's cloud-native enterprise health platform, and a Single-Ledger Model™, which increases visibility and reduces variability in drug prices. JUDI connects every aspect of the pharmacy ecosystem in one efficient, scalable platform, servicing over 2.4 million members for Medicare, Medicaid, and commercial plans. Together with our clients, we are reimagining the administration of pharmacy benefits and rebuilding trust in healthcare. **The drug recall report is subject to change: information in this report is current as of **4/24/2024****

Privacy Statement:

This privacy policy describes the types of information we may collect from you or that you may provide when you visit the website cap-rx.com and our practices for collecting, using, maintaining, protecting, and disclosing that information. Capital Rx, Inc. ("we," "our," or "us") is committed to ensuring that your privacy is protected. This policy applies to information we may collect through cap-rx.com, including any services offered on or through cap-rx.com such as the prescription benefit member web portal, and our mobile application accessible at the Google Play Store and iOS App Store under the name Capital Rx (collectively, our "Site").

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
4/03/2024	Class 2	Tri-Lo-Sprintec 0.18/0.215/0.25 Mg-25 Mcg Tablets	Teva Pharmaceuticals USA, Inc	00093-2140-62	100039678, EXP 04/31/2024; 100038111, 100042277, EXP 07/31/2024	Failing to meet dissolution specifications, which may result in possible issues with the tablets dissolving.
4/03/2024	Class 2	Divalproex Sodium Er 250 Mg Tb24	Amneal Pharmaceuticals of New York, LLC	65162-0755-10	AR210704, EXP 04/2024; AR210706, EXP 04/2024; AR210707, EXP 04/2024; AR210708, EXP 04/2024; AR210709, EXP 04/2024	Failing to meet dissolution specifications, which may result in possible issues with the tablets dissolving.

RECALL DATE	RECALL TYPE	DRUG RECALLED	MANUFACTURER	NDC(S) IMPACTED	IMPACTED LOT(S)	REASON FOR RECALL
4/10/2024	Class 2	Diltiazem Hcl Er 120 Mg Cp12	Glenmark Pharmaceuticals Inc., USA	68462-0562-01	17230304, EXP 12/31/2024	Failing to meet dissolution specifications, which may result in possible issues with the tablets dissolving.
4/17/2024	Class 2	Isotretinoin 40 Mg Capsules	Teva Pharmaceuticals USA, Inc	00591-2436-45, 00591-2436-15	100044259, EXP 06/30/2025	Failing testing that showed the drug was super potent (too strong).
4/24/2024	Class 1	Vancomycin HCl 250 MG/5ML Solution	Amneal Pharmaceuticals of New York, LLC	69238-2261-07, 69238-2261-05, 69238-2261-03	22613003A, EXP 09/30/2025; 22613004A, 22613005A, EXP 09/30/2025; 22613005B, EXP 09/30/2025	The potential for some bottles to be super potent (too strong), which may be harmful.

How do I find out more information about the recall? View the FDA website URL for more information.

RECALL TYPE	DRUG RECALLED	FDA NOTIFICATION URL
Class 2	Tri-Lo-Sprintec 0.18/0.215/0.25 Mg-25 Mcg Tablets	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=206530
Class 2	Diltiazem Hcl Er 120 Mg Cp12	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=206824
Class 2	Divalproex Sodium Er 250 Mg Tb24	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=206038
Class 2	Isotretinoin 40 Mg Capsules	https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=206873
Class 1	Vancomycin HCl 250 MG/5ML Solution	https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceuticals-llc-issues-nationwide-voluntary-recall-vancomycin-hydrochloride-oral-solution

